Jin-Shei Lai1,2, Mary Jo Kupst3, Jennifer L Beaumont1,4, Peter E Manley5, John Han-Chih Chang6, William F Hartsell7,8, Young Kwok9, Allison Piazza Fisher1, Stewart Goldman2,8. 1. Medical Social Sciences, Northwestern University Feinberg School of Medicine, Chicago, Illinois. 2. Pediatrics, Northwestern University Feinberg School of Medicine, Chicago, Illinois. 3. Pediatrics, Medical College of Wisconsin, Milwaukee, Wisconsin. 4. Terasaki Research Institute, Los Angeles, California. 5. Children's Hospital Boston and Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts. 6. Radiation Oncology, Vanderbilt University Medical Center, Nashville, Tennessee. 7. Northwestern Medicine Chicago Proton Center, Warrenville, Illinois. 8. Ann and Robert H. Lurie Children's Hospital of Chicago, Chicago, Illinois. 9. Radiation Oncology, University of Maryland School of Medicine, Baltimore, Maryland.
Abstract
BACKGROUND: Children with brain tumors can experience symptom burden throughout their disease continuum. The aim of the study was to evaluate symptom burden reported by children with brain tumors and factors that potentially were associated with their symptoms. METHODS: Data from 199 children with brain tumors aged 7-22 (mean age = 14 years; 52% males; 76% white) were analyzed. Symptom burden was assessed using the Patient-Reported Outcomes Measurement Information System (PROMIS) via computerized adaptive testing (CAT)-anxiety, depression, fatigue, mobility, upper extremity function, peer relationship, and cognition. Patients and parents completed Symptom Distress Scales (SDS). Test statistics and ANOVA were used to evaluate relationships between PROMIS measures and potentially influential variables. RESULTS: Significant results (P < 0.01) showing impact of symptom burden included: PROMIS measures correlated with SDSs reported by patients and parents on all comparisons. Fatigue, mobility, and upper extremity function were associated with Karnofsky functional performance status, number of treatment modalities (0-3), and time since last treatment (≤1 year, >1 year). Fatigue and cognition were associated with educational program (regular classroom without an individualized education plan vs those that had an individualized education plan); mobility and upper extremity function were associated with time since last radiation. Mobility, upper extremity function, and anxiety were associated with time since last chemotherapy. CONCLUSIONS: Significant associations were found between PROMIS and SDS as well as clinical and demographic characteristics. Brief-yet-precise PROMIS CATs can be used to systematically assess symptom burden experienced by children with brain tumors.
BACKGROUND:Children with brain tumors can experience symptom burden throughout their disease continuum. The aim of the study was to evaluate symptom burden reported by children with brain tumors and factors that potentially were associated with their symptoms. METHODS: Data from 199 children with brain tumors aged 7-22 (mean age = 14 years; 52% males; 76% white) were analyzed. Symptom burden was assessed using the Patient-Reported Outcomes Measurement Information System (PROMIS) via computerized adaptive testing (CAT)-anxiety, depression, fatigue, mobility, upper extremity function, peer relationship, and cognition. Patients and parents completed Symptom Distress Scales (SDS). Test statistics and ANOVA were used to evaluate relationships between PROMIS measures and potentially influential variables. RESULTS: Significant results (P < 0.01) showing impact of symptom burden included: PROMIS measures correlated with SDSs reported by patients and parents on all comparisons. Fatigue, mobility, and upper extremity function were associated with Karnofsky functional performance status, number of treatment modalities (0-3), and time since last treatment (≤1 year, >1 year). Fatigue and cognition were associated with educational program (regular classroom without an individualized education plan vs those that had an individualized education plan); mobility and upper extremity function were associated with time since last radiation. Mobility, upper extremity function, and anxiety were associated with time since last chemotherapy. CONCLUSIONS: Significant associations were found between PROMIS and SDS as well as clinical and demographic characteristics. Brief-yet-precise PROMIS CATs can be used to systematically assess symptom burden experienced by children with brain tumors.
Authors: Meghan Craven; Julia H Crowley; Lucas Chiang; Cassie Kline; Fatema Malbari; Matthew C Hocking; Shana E McCormack Journal: Front Endocrinol (Lausanne) Date: 2022-05-09 Impact factor: 6.055
Authors: Bryce B Reeve; Molly McFatrich; Jennifer W Mack; Laura C Pinheiro; Shana S Jacobs; Justin N Baker; Janice S Withycombe; Li Lin; Courtney M Mann; Katie R Villabroza; Pamela S Hinds Journal: Pediatr Blood Cancer Date: 2020-01-06 Impact factor: 3.167
Authors: Elizabeth D Cox; Sarah K Dobrozsi; Christopher B Forrest; Wendy E Gerhardt; Harald Kliems; Bryce B Reeve; Nan E Rothrock; Jin-Shei Lai; Jacob M Svenson; Lindsay A Thompson; Thuy Dan N Tran; Carole A Tucker Journal: J Pediatr Date: 2020-11-30 Impact factor: 4.406